Daiwa analyst Narumi Nakagiri downgraded Pfizer (PFE) to Neutral from Outperform with a $27 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Wells says near-term TrumpRx monetization unlikely material for GoodRx
- Entera Bio appoints Geno Germano as chairman of the board
- Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults: What Investors Should Know
- Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
- H.C. Wainwright says Chantix news ‘significant win’ for Achieve Life Sciences